News Conference News AHA 2025 CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia Todd Neale November 08, 2025
News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Conference News AHA 2024 Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III Caitlin E. Cox November 21, 2024
News Conference News AHA 2024 Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360 Michael O'Riordan November 18, 2024
News Conference News AHA 2024 Lipid Fluctuations Over Time May Portend Dementia: ASPREE Yael L. Maxwell November 15, 2024
News Conference News AHA 2023 Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV Todd Neale November 17, 2023
News Conference News AHA 2023 Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing Shelley Wood November 14, 2023
News Conference News AHA 2021 ApoB Gains Ground as Best Lipid Predictor of MI Risk Michael O'Riordan November 22, 2021
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Conference News AHA 2019 EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl Todd Neale November 18, 2019
News Conference News AHA 2019 COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine Caitlin E. Cox November 16, 2019
News Conference News AHA 2017 CANTOS: Big Drop in CVD Events Among Canakinumab Responders Michael O'Riordan November 13, 2017
News Conference News AHA 2015 Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact Todd Neale November 12, 2015